MD, Deputy Director, Department of Radiation Oncology, IRCCS San Raffaele Scientific Institute, Milan Contract Professor Vita-Salute San Raffaele University
I thank Estro for the opportunity to present the preliminary results of the PRO-FAST trial, one of the few in the world of single-fraction prostate radiotherapy . Convenient for patients, the entire procedure is completed in one day, with low toxicity and excellent PSA control.
A drone captured the incredible moment a whale pushed a paddleboard with its fin.
Maximiliano Jonas filmed the amazing footage off the coast of Puerto Madryn, Argentina
[📹 maxijonas]
ZERO cases of cervical cancer diagnosed in women under age 25 in Australia 🇦🇺
None . Nada . Zip.
For the first time since records began!
How did this happen?
One word
VACCINES!!!!!
In localized radiorecurrent #ProstateCancer, salvage focal therapy provided similar 10-year survival outcomes as radical prostatectomy but resulted in substantially fewer perioperative complications.
https://t.co/6vnhJWbElx
1/ Thank you 🙏🏾, patients, families, and investigators, for contributing to the SEISMIC 🫁trial out now @LancetRespirMed - https://t.co/orK2owgN2T. Led by 🫁@DanSteinfort, this international multicentre recruited n=155 trial from 🇦🇺, 🇨🇦, 🇺🇸, 🇳🇱 #radonc@tssmn@PeterMacRadOnc
❓ What is the optimal duration of ADT if combined with EBRT for definitive treatment of prostate cancer
Virtual Grand Rounds in Radiation Oncology
🎙 Speaker: Dr. @NicholasZaorsky
📅 February 4th, 5 - 5.30 pm CET
💻 Join us virtually here: 👇
https://t.co/LnWKWLtxNz
Radiotherapy for Unresectable Locally Advanced Non-Small Cell Lung Cancer: A Practical Multidisciplinary Approach to Challenging Scenarios from the IASLC Advanced Radiation Technology (ART) Subcommittee - Journal of Thoracic Oncology https://t.co/adoSHuiSIu
🚀 Early data from the #STARRtrial (NCT05455736) show promising results for SSRT in macroscopic prostate bed recurrence post-prostatectomy—without ADT!
📉 82.6% complete biochemical response
✅ Mild toxicity
⚡️ Fast, focused, and well-tolerated #EMUC2025@NiccolBertini2
#astro25@NRGonc Rtog 0924 trial on 2500 patients testing whole pelvic RT.
Negative trial
-OS no difference
-PCSM no difference
-DM no difference
-BCR was not SS different with only 4% difference at 10 years.
-toxicity increased
3 cooperative group trials now negative: getug01, Rtog 9413, Rtog 0924.
Goodbye WPRT
Two-year clinical outcomes following ablative radiotherapy for unfavorable prostate tumors (ABRUPT). Presented by @StAr_MCM74@unimib. #ASTRO25 written coverage by @RKSayyid@UAUrology > https://t.co/g3iTO4MELE @ASTRO_org